


One Vector – Unlimited possibilities against infectious diseases and cancer

From concept to clinic: Rapid development of vaccines and immune modulation approaches



Company Overview

Themis has developed a sophisticated vaccine platform and broad pipeline based on advanced understanding of immune modulation mechanisms. Initially focused on preventing infectious diseases, the company leads in the development of a vaccine against Chikungunya, a serious debilitating disease with global outbreak potential. With the lead vaccine candidate moving towards Phase 3 trials, Themis will leverage its advanced antigen design expertise coupled with its proprietary vector's immune activation potential to address other serious infectious diseases and oncology targets. Themis' vision is to work together with industrial and academic partners to prevent and treat illness across the globe.


Themis at a Glance

1. **The proven platform** combines the powerful immune modulating capability of a safe, cost-effective and a proven delivery vector with advanced antigen design and **commercial-ready manufacturing system**
2. Results from the Phase 2 trial for its lead product against Chikungunya will be communicated in 2018
3. **Backed by prestigious venture funds** and has raised over € 20 million to support its growth and development
4. Received **over € 37 million from the Coalition for Epidemic Preparedness Innovations (CEPI)** through a partnership to develop and manufacture vaccines against Lassa fever and Middle East Respiratory Syndrome (MERS)
5. An **experienced team of business and vaccine development experts** to advance its current clinical programs and expand its pipeline


Chikungunya Vaccine – Technology Proof-of-Concept

Themis has the world-leading vaccine in development against Chikungunya, a viral disease posing a growing risk worldwide. The Chikungunya virus is transmitted to humans via infected mosquitoes and causes large outbreaks with infection rates of up to 90%. Themis has demonstrated in over 600 subjects worldwide that its

Chikungunya vaccine candidate is well tolerated and has an excellent immunogenicity and safety profile. Preparation for Phase 3 clinical development is currently underway and the company plans to submit for regulatory approval within the next 2 to 3 years.



Technology Potential



Immune Shield

Themis' versatile technology platform is applicable across a wide range of infectious diseases and other immunology indications, including cancer. As a cornerstone of the technology, Themis uses the approved measles vaccine vector with decades of safety data in billions of humans.


One Vector, Unlimited Possibilities

1. The platform has a proven track record of producing innovative vaccine candidates with high potency and safety

2. A feature of Themis' technology is the inherent ability of its live attenuated replicating vector to elicit a powerful cellular and humoral immune response that is designed to confer long-term immunity
3. Themis has the ability to incorporate large recombinant genes coding for an unlimited number of selected antigens into the vector's genome
4. Themis has also developed an efficient and robust, commercial-ready manufacturing infrastructure, which can be rapidly re-purposed for new products

Our Pipeline – Equipped to Deliver

Themis has established a versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches.



Management Team, BOD, Key Investors

Management Team and Scientific Leadership

Erich Tauber, Ph.D., *Chief Executive Officer*
 Philippe Dro, Ph.D., *Chief Business Officer*
 Lee Smith, Ph.D., *Chief Technical Officer*
 Katrin Ramsauer, Ph.D., *SVP Research & Development*
 Alexander Kort, *SVP Corporate Development*
 David Maier, Ph.D., *SVP Finance*
 Christian Mandl, M.D., Ph.D.,
Chairman Scientific Advisory Board

Board of Directors

Gerd Zettlmeissl, Ph.D., *Chairman*
 Mounia Chaoui, Ph.D.
 Regina Hodits, Ph.D.
 Ralf Kunzmann
 Jean Paul Prieels, Ph.D.
 Glenn Rockman
 Maximilien Fournier Sourdillev

Investors



Partners



Contact



Themis Bioscience GmbH
 Muthgasse 11/2, 1190 Vienna, Austria
 +43 1 236 7151
 office@themisbio.com

www.themisbio.com
[in www.linkedin.com/company/themisbio](https://www.linkedin.com/company/themisbio)
[@Themis_Bio](https://twitter.com/Themis_Bio)